| Literature DB >> 35821657 |
Jason A Toy1, Kristy J Kroeker1, Cheryl A Logan2, Yuichiro Takeshita3, Gary C Longo1,4, Giacomo Bernardi1.
Abstract
Acidification-induced changes in neurological function have been documented in several tropical marine fishes. Here, we investigate whether similar patterns of neurological impacts are observed in a temperate Pacific fish that naturally experiences regular and often large shifts in environmental pH/pCO2 . In two laboratory experiments, we tested the effect of acidification, as well as pH/pCO2 variability, on gene expression in the brain tissue of a common temperate kelp forest/estuarine fish, Embiotoca jacksoni. Experiment 1 employed static pH treatments (target pH = 7.85/7.30), while Experiment 2 incorporated two variable treatments that oscillated around corresponding static treatments with the same mean (target pH = 7.85/7.70) in an eight-day cycle (amplitude ± 0.15). We found that patterns of global gene expression differed across pH level treatments. Additionally, we identified differential expression of specific genes and enrichment of specific gene sets (GSEA) in comparisons of static pH treatments and in comparisons of static and variable pH treatments of the same mean pH. Importantly, we found that pH/pCO2 variability decreased the number of differentially expressed genes detected between high and low pH treatments, and that interindividual variability in gene expression was greater in variable treatments than static treatments. These results provide important confirmation of neurological impacts of acidification in a temperate fish species and, critically, that natural environmental variability may mediate the impacts of ocean acidification.Entities:
Keywords: RNA-seq; climate change; differential gene expression; embiotocidae; environmental variability; global change
Mesh:
Substances:
Year: 2022 PMID: 35821657 PMCID: PMC9545418 DOI: 10.1111/mec.16611
Source DB: PubMed Journal: Mol Ecol ISSN: 0962-1083 Impact factor: 6.622
FIGURE 1Experiment design and data analysis pipeline for Experiments 1 and 2.
Carbonate chemistry and environmental parameters for treatment containers in Experiment 1
| Treatment | pHT (spec) |
| Ω | TA (μmol/kg) | Temp (°C) | Salinity (ppt) | pHT (YSI) |
|---|---|---|---|---|---|---|---|
| Target pH 7.85 | 7.88 ± 0.02 | 599 ± 36 | 1.50 ± 0.08 | 2193 ± 59 | 13.0 ± 0.5 | 33.8 ± 0.1 | 7.89 ± 0.04 |
| Target pH 7.30 | 7.35 ± 0.06 | 2204 ± 333 | 0.48 ± 0.07 | 2212 ± 20 | 12.2 ± 0.8 | 33.8 ± 0.1 | 7.36 ± 0.14 |
Note: Aragonite saturation state (Ω) and pCO2 were calculated with the R package seacarb (Gattuso et al., 2021) using the spectrophotometric pH and total alkalinity (TA) values from discrete bottle samples, and salinity and temperature values from YSI readings. All values are means ± SD. Mean pHT (spec) and TA were calculated from bottle samples taken at seven time points across the experiment. Mean pHT (YSI) was calculated from daily readings that were calibrated using the discrete bottle samples.
Carbonate chemistry and environmental parameters for the headers of each treatment in Experiment 2
| Treatment | pHT (Durafet) (hourly) |
| Ω | TA (μmol/kg) (bottle samples) | Temp (°C) (Durafet) | Salinity (ppt) (YSI) | pHT (YSI) (daily) |
|---|---|---|---|---|---|---|---|
| Ambient | 8.00 ± 0.04 | 452 ± 55 | 2.36 ± 0.23 | 2266 ± 3 | 17.5 ± 0.06 | 34.3 ± 0.1 | 8.01 ± 0.08 |
| Target pH 7.85 ‐ Static | 7.90 ± 0.01 | 586 ± 14 | 1.94 ± 0.07 | 2268 ± 3 | 17.6 ± 0.06 | 34.3 ± 0.1 | 7.90 ± 0.05 |
| Target pH 7.85 ‐ Variable | 7.89 ± 0.08 | 614 ± 136 | 1.93 ± 0.34 | 2268 ± 4 | 17.5 ± 0.06 | 34.3 ± 0.1 | 7.88 ± 0.11 |
| Target pH 7.70 ‐ Static | 7.76 ± 0.04 | 848 ± 64 | 1.46 ± 0.17 | 2268 ± 5 | 17.6 ± 0.06 | 34.3 ± 0.1 | 7.75 ± 0.08 |
| Target pH 7.70 ‐ Variable | 7.76 ± 0.09 | 870 ± 199 | 1.47 ± 0.30 | 2267 ± 4 | 17.6 ± 0.06 | 34.3 ± 0.1 | 7.74 ± 0.10 |
Note: Aragonite saturation state (Ω) and pCO2 were calculated with the R package seacarb (Gattuso et al., 2021) using the Durafet pH and temperature values, average TA values from discrete bottle samples, and salinity values from YSI readings. All values are means ± SD. Mean pHT (Durafet) values were calculated using hourly averaged pH readings (from headers) that were calibrated using discrete (bottle) water samples and include only the time period of the first two pH cycles (1/2 September–17/18 September). Mean pHT (YSI) values were calculated using daily readings (from replicate containers) that were calibrated using bottle‐calibrated Durafet values (taken simultaneously) from the 1/2 September–17/18 September date range and include YSI readings from the entire length of the experiment (1/2 September–23/24 September).
FIGURE 2Heatmap of gene expression profiles for each individual in Experiment 1. Each column represents an individual fish, and each row represents a differentially expressed gene. Yellow colours represent upregulation in a given treatment and purple colours represent downregulation. Brighter hues represent larger differences in relative gene expression across the treatments.
Number of DEGs detected across all treatment comparisons in Experiment 2
| Ambient | pH 7.70 static | pH 7.70 variable | pH 7.85 static | |
|---|---|---|---|---|
|
| ||||
|
| 5 | |||
|
| 8 | 6 | ||
|
| 3 | 159 | 11 | |
|
| 6 | 11 | 9 | 6 |
FIGURE 3nMDS plot of DEG expression in Experiment 2. Points represent single individuals. Ellipses are 95% confidence ellipses.
FIGURE 4Box plot of within‐treatment variances in Experiment 2 (DEGs only, outliers removed for clarity). Diamonds mark the mean for each treatment. Notches represent a roughly 95% confidence interval around the median. Removed points lie outside of 1.5 times the IQR of each hinge.
Summary of upregulated and downregulated gene set clusters in Experiment 1
| Upregulated in pH 7.30 treatment | Downregulated in pH 7.30 treatment | ||
|---|---|---|---|
| Categorical cluster | Number of gene sets in each cluster | Categorical cluster | Number of gene sets in each cluster |
| Mitochondrion, aerobic respiration, mRNA export from nucleus | 44 | Transmembrane ion transport, regulation of synaptic signalling, ligand‐gated ion channel activity, behaviour, cognition and sensory perception | 90 |
| RNA metabolism, processing, splicing, modification, tRNA biosynthesis; ribosome biogenesis | 41 | Regulation of nervous system development and growth | 60 |
| Translation and protein localization | 39 | Synaptic vesicle membrane, regulation of clathrin‐dependent endocytosis | 22 |
| Muscle development | 22 | Axo‐dendritic transport | 20 |
| Organic acid catabolism | 15 | Synaptic membrane and synapse | 19 |
| Muscle contraction and adaptation, myogenesis | 14 | G protein‐coupled receptor signalling | 15 |
| Energy reserve and carbohydrate metabolic process | 10 | Exocytosis and secretion | 14 |
| Proteolysis, mRNA catabolism, negative regulation of cell cycle G2/M phase transition | 10 | Central nervous system development | 12 |
| Peroxisomal organization and transport, protein localization to organelle | 8 | Regulation of pH and iron ion transport | 9 |
| Innate immune response | 6 | Aminoglycan and glycoprotein metabolic process | 8 |
| Telomere maintenance via lengthening and organization | 6 | Calcium‐dependent phospholipid binding and cell–cell adhesion | 8 |
| RNA polymerase II | 5 | Dopamine secretion and transport | 7 |
| Protein modification by small protein conjugation or removal | 3 | Axon, distal axon and terminal bouton | 6 |
| Actin filament binding | 2 | Dendritic tree and neuron spine | 6 |
| Alpha actinin binding | 2 | GTPase activator activity | 6 |
| Cytoplasmic stress granule | 2 | Positive regulation of MAPK cascade | 6 |
| DNA polymerase activity | 2 | Receptor localization to synapse | 6 |
| Mitochondrial matrix and nucleoid | 2 | Regulation of vesicle fusion | 6 |
| Ribosome binding | 2 | Dendrite membrane | 5 |
| RNA helicase activity | 2 | Ephrin receptor signalling pathway | 5 |
| adipogenesis | 1 | Extrinsic component of cytoplasmic side of plasma membrane | 5 |
| ADP binding | 1 | Microtubule polymerization | 5 |
| Allograft rejection | 1 | Regulation of protein localization to membrane | 5 |
| Androgen response | 1 | Synaptic vesicle transport and localization | 5 |
| Cell substrate junction | 1 | Glycosphingolipid biosynthetic process | 4 |
| Cysteine‐type endopeptidase activity | 1 | Cortical Actin cytoskeleton | 3 |
| Fatty acid metabolism | 1 | Regulation of cell shape | 3 |
| Ficolin‐1‐rich granule lumen | 1 | Vascular transport | 3 |
| General transcription initiation factor binding | 1 | Intrinsic component of Golgi membrane | 2 |
| Interferon alpha response | 1 | Long term depression and vascular smooth muscle contraction | 2 |
| Lysine degradation | 1 | Negative regulation of secretion & transport | 2 |
| MYC targets version 1 (Hallmark) | 1 | Neuron apoptotic process | 2 |
| MYC targets version 2 (Hallmark) | 1 | Regulation of amyloid precursor protein catabolic process | 2 |
| Platelet morphogenesis | 1 | Regulation of neurotransmitter receptor activity | 2 |
| Positive regulation mitotic cell cycle | 1 | Regulation of small GTPase‐mediated signal transduction | 2 |
| Receptor signalling pathway via STAT | 1 | Response to catecholamine | 2 |
| rRNA binding | 1 | Synaptic vesicle recycling | 2 |
| Sarcolemma | 1 | Vesicle docking | 2 |
| Sarcoplasm | 1 | Amyotrophic lateral sclerosis | 1 |
| Starch & sucrose metabolism | 1 | Anchored component of membrane | 1 |
| Viral myocarditis | 1 | Cyclic nucleotide‐mediated signalling | 1 |
| developmental maturation | 1 | ||
| Endocytosis | 1 | ||
| Gap junction | 1 | ||
| Genes upregulated by KRAS activation | 1 | ||
| Kinesin binding | 1 | ||
| Long‐term potentiation | 1 | ||
| Neuron migration | 1 | ||
| Perinuclear region of cytoplasm | 1 | ||
| Phosphoprotein binding | 1 | ||
| Phosphoric diester hydrolase activity | 1 | ||
| Protein serine threonine kinase inhibitor activity | 1 | ||
| Regulation of neuron differentiation | 1 | ||
| Renal system process | 1 | ||
| Tau protein binding | 1 | ||
Note: Enriched gene sets (GO, KEGG, hallmark) were clustered by similarity using the AutoAnnotate and clusterMaker2 applications for the Cytoscape software platform. Clusters were then manually examined and named. See Table S12 for the full list of enriched gene sets in this experiment.
Summary of upregulated and downregulated gene set clusters in Experiment 2 (comparison of static treatments
| Upregulated in pH 7.70 treatment | Downregulated in pH 7.70 treatment | ||
|---|---|---|---|
| Categorical cluster | Number of gene sets in each cluster | Categorical cluster | Number of gene sets in each cluster |
| RNA processing & splicing, histone methyltransferase complex | 26 | Immune response | 34 |
| Epigenetic regulation of gene expression and chromatin organization | 8 | Lymphocyte proliferation, differentiation and activation | 26 |
| DNA repair, recombination and replication | 7 | Secretory granule and myeloid leucocyte mediated immunity | 13 |
| mRNA export from nucleus | 6 | Endothelial cell migration and blood vessel morphogenesis | 10 |
| E‐box binding | 4 | JAK–STAT signalling pathway | 9 |
| Ubiquitin‐mediated proteolysis | 4 | Neuropeptide/G protein‐coupled receptor signalling pathway | 7 |
| Ubiquitin ligase complex | 4 | Cellular ion homeostasis | 6 |
| RNA phosphodiester bond hydrolysis | 3 | Positive regulation of MAPK cascade | 6 |
| Gene silencing | 2 | Cell–cell junction assembly | 5 |
| Nuclear speck | 2 | Developmental growth involved in morphogenesis | 5 |
| A band | 1 | Regulation of cytoskeleton and supramolecular fibre organization | 5 |
| Cell cortex region | 1 | Wound healing and regulation of body fluid levels | 5 |
| Inositol phosphate‐mediated signalling | 1 | Leucocyte migration and regulation of chemotaxis | 4 |
| Regulation of long‐term synaptic potentiation | 1 | External side of plasma membrane | 3 |
| Single‐stranded RNA binding | 1 | Leading edge membrane | 3 |
| Structural constituent of cytoskeleton | 1 | Plasma membrane signalling receptor complex | 3 |
| Transcription coregulator activity | 1 | Positive regulation of phagocytosis | 3 |
| Protein complex involved in cell adhesion and integrin‐mediated signalling pathway | 3 | ||
| Regulation of cytokine production | 3 | ||
| Cilium movement and cell motility | 2 | ||
| Collagen‐containing extracellular matrix | 2 | ||
| Endocytic vesicle | 2 | ||
| Positive regulation of cell‐substrate adhesion | 2 | ||
| Receptor‐mediated endocytosis | 2 | ||
| Regulation of peptidyl‐tyrosine phosphorylation | 2 | ||
| Guanyl nucleotide binding | 1 | ||
| Calcium ion binding | 1 | ||
| Allograft rejection | 1 | ||
| Membrane microdomain | 1 | ||
| Complement system | 1 | ||
| Positive regulation of cell population proliferation | 1 | ||
| Smooth muscle contraction | 1 | ||
| Superoxide metabolic process | 1 | ||
| Response to organophosphorus | 1 | ||
| Ras protein signal transduction | 1 | ||
| Response to dopamine | 1 | ||
| Inflammatory response | 1 | ||
| Odontogenesis | 1 | ||
| Coagulation | 1 | ||
| Leucocyte transendothelial migration | 1 | ||
| Pigment granule | 1 | ||
| Cell adhesion molecule binding | 1 | ||
| Ciliary plasm | 1 | ||
Note: Enriched gene sets (GO, KEGG, hallmark) were clustered by similarity using the AutoAnnotate and clusterMaker2 applications for the Cytoscape software platform. Clusters were then manually examined and named. See Table S13 for the full list of enriched gene sets in this experiment.
FIGURE 5Overlapping enriched gene sets across both experiments. “Up” and “down” refer to gene sets that were up‐ or downregulated in the lower pH treatment relative to the higher pH treatment in each experiment (i.e., pH 7.85 treatments are treated as baseline in both cases). Only static treatments are included for Experiment 2.
Overlapping enriched gene sets between high pH versus low pH comparisons in Experiments 1 and 2 (upregulated vs. downregulated gene sets in both experiments)
| Upregulated in both experiments | Downregulated in both experiments |
|---|---|
| GOBP ribonucleoprotein complex biogenesis | GOBP MAPK cascade |
| GOBP ncRNA processing | GOCC side of membrane |
| GOCC ribonucleoprotein complex | GOBP receptor mediated endocytosis |
| GOMF catalytic activity acting on RNA | GOCC cell surface |
| GOBP translational termination | GOBP positive regulation of protein kinase activity |
| GOBP RNA export from nucleus | GOBP positive regulation of MAPK cascade |
| GOBP RNA processing | GOCC cell leading edge |
| GOBP RNA phosphodiester bond hydrolysis | GOBP cell |
| GOBP mRNA export from nucleus | GOBP cell |
| GOBP nuclear export | GOBP endocytosis |
| GOBP mRNA metabolic process | GOBP exocytosis |
| GOCC U2 type spliceosomal complex | GOBP cell |
| GOBP RNA 3′‐end processing | GOBP cell growth |
| GOBP nucleic acid phosphodiester bond hydrolysis | GOBP taxis |
| KEGG spliceosome | GOCC secretory granule membrane |
| GOCC transferase complex | GOBP regulation of anatomical structure morphogenesis |
| GOBP protein modification by small protein conjugation | GOCC secretory vesicle |
| GOBP RNA localization | GOMF neuropeptide receptor activity |
| GOCC spliceosomal complex | GOBP cell junction assembly |
| GOBP protein modification by small protein conjugation or removal | KEGG cell adhesion molecules cams |
| GOBP RNA splicing | GOCC plasma membrane protein complex |
| GOBP mRNA processing | GOMF calcium ion binding |
| GOCC nuclear protein‐containing complex | GOCC cell projection membrane |
| GOCC intracellular protein‐containing complex | GOCC plasma membrane signalling receptor complex |
| GOBP cell | |
| GOBP developmental growth involved in morphogenesis | |
| GOBP developmental cell growth | |
| GOBP neuropeptide signalling pathway | |
| GOBP adenylate cyclase inhibiting G protein‐coupled receptor signalling pathway | |
| GOCC leading edge membrane | |
| GOCC vesicle membrane | |
| GOMF G protein‐coupled receptor activity | |
| GOCC receptor complex | |
| KEGG neuroactive ligand receptor interaction | |
| GOBP G protein‐coupled receptor signalling pathway | |
| GOMF molecular transducer activity |
FIGURE 6Overlapping enriched gene sets across static versus variable comparisons in Experiment 2. “Up” and “down” refer to gene sets that were up‐ or downregulated in the “variable” treatment relative to the “static” treatment for a given pH level (7.85 or 7.70; i.e., static treatments are treated as baseline).